Empowering the world with transformative technologies to fight against infectious disease

Defending against pandemics, biothreats and emerging infectious diseases

Covid-19 Response

Compassionate use

BOA Biomedical maintains a Compassionate Use (also called Expanded Access) program for circumstances where a patient with a life-threatening illness, such as COVID-19, requires treatment and the treating physician believes that the GARNET technology may be of benefit. Read Policy.

Advanced Innovation

Detect

Rapid
detection

Recognize active infection and assess infection severity and sepsis within minutes in any setting, including the home.

Diagnose

Rapid pathogen identification

Accurately identify infection-causing pathogens, within one hour, without the need for blood cultures.

Treat

Pathogen toxin removal

Filter the toxic by-products of pathogens directly from a patient’s blood using an extracorporeal therapeutic filter.

World class collaborations in the fight against infectious disease

BOA, DOD and their research agency, DARPA, focus research on diagnosing and treating sepsis. BOA licensed the technology from Harvard University in 2018 and was awarded emergency grants from the Department of Defense in 2020.

BOA Biomedical, a Miraki Innovation company has licensed technology from Harvard’s Wyss Institute to develop devices that can diagnose and treat infectious diseases.